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cense.Abstract Background: Angiogenesis is an essential process in cancer growth maintenance, and
metastasis. Angiopoietin-2 promotes tumor angiogenesis by priming the vasculature and potentiat-
ing the effects of cytokines at the front of active neovascularization. Enhanced expression of angio-
poietin-2 has been reported in lung cancer tissue. Survivin is one of the inhibitors of apoptosis
protein that has been shown to play a key role in cancer progression, and in tumor angiogenesis.
Also plays a key role in tumor cell resistance to anticancer agents and ionizing radiation.
Aim: To measure the serum levels of angiopoietin-2 and survivin as possible angiogenic factors in
lung cancer patients with the assessment of their interrelationships and clinical signiﬁcance.
Patients and methods: Patients with lung cancer as NSCLC (n= 70) and healthy volunteers
(n= 10) were enrolled. Serum angiopoietin-2 and survivin concentrations were measured using
enzyme-linked immunosorbent assay (ELIZA).
Results: Median serum angiopoietin-2 levels with lung cancer (2730 pg/mL) ranged from 1171 to
6541 pg/mL was higher than the median of the control group (1795 pg/mL) ranged from 1076 tolung cancer; ROC, Receiver
ly Gendy, 6th district, Nasr






42 A. Fawzy et al.2730/mL, p< 0.001. Median serum survivin levels were also higher in patients with lung cancer
(53.0 pg/mL) ranged from 39.3 to 96.3 pg/mL than the median of the control group (48.8 pg/mL)
ranged from 38.0 to 74.6 pg/mL, but did not reach statistical signiﬁcance p= 0.206.
In all patients with lung cancer, serum angiopoietin-2 was not signiﬁcantly correlated with survivin
(r= 0.073, p= 0.657). Neither serum angiopoietin-2 nor survivin showed signiﬁcant relation with
the serum angiopoietin-2 or survivin levels depending on the cell types, stage progression, and
metastasis among the patients with NSCLC.
Conclusions: Our study suggests that serum angiopoietin-2 is a useful marker for the diagnosis of
NSCLC by ELIZA technique.
ª 2012 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Table 1 Demographic characteristics of NSCLC and control
groups.
Variables NSCLC Control p-Value
Age, yrs (mean ± SD) 57.8 ± 11.5 65.3 ± 8.6 0.271
Male gender (No, %) 54 (77%) 6 (60%) 0.077
Smoker (No, %) 65 (92%) 0 <0.001
SD: Standard Deviation.Introduction
Lung cancer is one of the most common causes of cancer-re-
lated deaths around the world with non-small lung cancer rep-
resenting approximately 80% of the cases [1].
Angiogenesis is an essential process in cancer growth, main-
tenance, and metastasis [2]. The tumor vessel density, which
represents angiogenesis, is related to metastasis and has prog-
nostic value in various malignant tumors, including lung can-
cer. Angiogenesis is controlled by the interplay of numerous
positive and negative factors [3].
Angiopoietins play an important role in angiogenesis.
Angiopoietin-1 and 2 act as ligands for Tie2, which is a tyro-
sine kinase receptor speciﬁcally expressed on endothelial cells
[4]. Angiopoietin-1 stabilizes blood vessels by promoting the
interaction between endothelial cells and the surrounding
extracellular matrix [5]. On the other hand angiopoietin-2
antagonizes the stabilizing action of angiopoietin-1 by binding
to Tie2 competitively, which destabilizes vessels. It also pro-
motes tumor angiogenesis by priming the vasculature and
potentiating the effects of cytokines at the front of active neo-
vascularization [6].
Angiopoietin-2 is preferentially expressed in lung cancer tis-
sues while angiopoietin-1 and Tie2 are predominantly ex-
pressed in normal lung tissue [5]. Furthermore, the levels of
angiopoietin-2 expression are associated with prognosis [7]
however, the serum levels of angiopoietins have not been eval-
uated in lung cancer.
Survivin is one of the human inhibitors of apoptosis protein
(IAP) which has been identiﬁed. It contains one or more bac-
ulovirus IAP repeat domains, which are necessary to bind spe-
ciﬁcally to a terminal effectors cell-death protease (e.g.,
caspase-3 and -7). This binding substantially reduces caspase
activity and reduces cell death in response to a variety of apop-
totic stimuli [8].
Survivin which a 16.5-kDa is highly expressed in cancer
cells and transformed cells, but shows little or no expression
in normal differentiated tissues. It has been found to be ex-
pressed in tissues during fetal development and selectively in
cancer cells in many common human neoplasms [9]. Function-
ally, survivin has been shown to play a key role in cancer pro-
gression, tumor cell resistance to anticancer agents and
ionizing radiation [10]. Moreover, survivin has been suggested
as tumor marker in the diagnosis and prognosis of many com-
mon cancers [11]. It also plays a key role in tumor angiogenesis
because it is strongly expressed in endothelial cells during the
remodeling and proliferative phase [12].In NSCLC, reports revealed that gene transcript was either
identiﬁed or shown to be massively elevated in a majority of
NSCLC cases [13]. Several studies have been carried out that
suggest that survivin could serve as a potential tumor marker
in evaluating recurrence and prognosis of patients with
NSCLC [13–15].
Measurement of the serum levels of angiopoietin-2 and sur-
vivin as possible angiogenic factors in lung cancer patients was




This study included 70 patients newly diagnosed non-small cell
lung (NSCLC), presenting at the National Cancer Institute,
Cairo University outpatient clinics from January to August
2010 and 10 healthy volunteers as control group.
Baseline demographic characteristics of the studied groups
were presented in Table 1. Serum samples from each individual
were obtained at the time of diagnosis before any therapeutic
measures were started. Sera were stored at 80 C.
The diagnosis of lung cancer was made using various meth-
ods such as: Sputum cytology, thoracocentesis, ﬁne-needle
aspiration, or bronchoscopy. Pathologists interpreted the
cytology or histology of tissue biopsy. Lung cancer was staged
using a widely used classiﬁcation system [16] and the staging
procedure included the clinical examination; standard chest
radiography; CT of the chest, abdomen and bronchoscopy.
Brain CT or MRI; bone scanning; and positron emission
tomography were requested whenever indicated. For precise
staging, in NSCLC at stage IIIa or under, only patients in
whom pathologic staging was possible due to resection surgery
were selected. For cases not eligible for surgical resection,
imaging modalities were used for staging.
Importance of serum levels of angiopoietin-2 and survivin biomarkers in non-small cell lung cancer 43Enzyme-linked immunosorbent assays were used to mea-
sure angiopoietin-2 and survivin (Quantikine Immunoassay
R&D System, USA).
This study was approved by the Institutional Review Board
of NCI. Written informed consent was obtained before enroll-
ment into the study.
Statistical methods
Data were analyzed using SPSSwin statistical package version
15 (SPSS Inc., Chicago, IL). Chi-square test (Fisher’s exact
test) was used to examine the relation between qualitative vari-
ables. For quantitative data, comparison between two groups
was done using Mann–Whitney test. Comparison between
three groups was done using Kruskal–Wallis test. Spearman–
rho method was used to test correlation between numerical
variables. The Receiver Operating Characteristic (ROC) curve
was used for the prediction of cut off values of the markers. A
p-value <0.05 was considered signiﬁcant.
Results
Serum angiopoietin-2 and survivin in lung cancer patients and
control subjects
Median serum angiopoietin-2 levels with lung cancer (2730
pg/mL) ranged from 1171 to 6541 pg/mL was higher than
the median of the control group (1795 pg/mL) ranged from
1076 to 2730/mL, p< 0.001 Fig. 1.
Median Serum survivin levels were also higher in patients
with lung cancer (53.0 pg/mL) ranged from 39.3 to 96.3
pg/mL than the median of the control group (48.8 pg/mL) ran-
ged from 38.0 to 74.6 pg/mL, but did not reach statistical sig-
niﬁcance p= 0.206.
In all patients with lung cancer, serum angiopoietin-2 was
not signiﬁcantly correlated with survivin (Spearman
r= 0.073, p= 0.657).
Also neither serum angiopoietin-2 nor survivin showed sta-
tistically signiﬁcant difference between different cell types
among the patients with NSCLC (Table 2).
Relation of serum angiopoietin-2 and survivin with different
prognostic factors
Relation of serum angiopoietin-2 and survivin was tested with




















Figure 1 Serum angiopoietin-2 level in lung cancer patients and
control.patients with NSCLC. None of these parameters showed sig-
niﬁcant relation with the serum angiopoietin-2 or survivin lev-
els (Table 3).ROC analysis of serum angiopoietin-2 and survivin
ROC curves for serum angiopoietin-2 and survivin concentra-
tions were constructed to choose the cutoff values. The area
under the curve for serum angiopoietin-2 was 0.832 while that
of survivin was 0.672. At a cutoff value of 2096 pg/mL the sen-
sitivity and speciﬁcity of serum angiopoietin-2 levels in lung
cancer patients were 76.6% and 80.0%, respectively, while
those for serum survivin level, at a cutoff value of 49.5 pg/
mL were 72.3% and 60.0%, respectively relative to the control
group (Figs. 2 and 3).Discussion
Angiogenesis is an important process in carcinogenesis, and it
plays a major role in lung cancer [17,18].
In tumors, a shift in the balance between pro- and anti-
angiogenic factors is thought to occur; termed the ‘angiogenic
switch’ resulting in an angiogenic phenotype [19]. It has been
proposed that a change in the ratio of Ang-1:Ang-2 in favor
of Ang-2 might play a role in this switch [20].
Although malignant tumors undergo massive tumor cell
loss via central regression and necrosis, the remaining tumor
grows via active angiogenesis at the tumor margin. Angiopoie-
tin-2 is reported as a critical regulators of this angiogenic pro-
cess [21,22]. VEGF up-regulation along with angiopoietin-2
expression at the tumor periphery is associated with rescuing
the surviving tumor and promoting further growth. Speciﬁ-
cally, angiopoietin-2 is strongly induced in the peripheral ves-
sels of tumor tissues before VEGF induction [4].
Angiopoietin-2 operates in tumor angiogenesis, and it’s
over expression in lung cancer tissue is related to a poor prog-
nosis [17]. Also, it has been shown to be a marker of a poor
prognosis in breast cancer and non-small cell lung cancer
[4,20,23]. However, very few studies have examined the clinical
implications of serum angiopoietin-2 levels in lung cancer.
This study showed that angiopoietin-2 was important for
differentiating non-small cell lung cancer from control sub-
jects. This result is in agreement with Park et al. [17] that stud-
ied Serum angiopoietin and VEGF in 110 patients with
NSCLC and 40 healthy volunteers and up to our knowledge;
this is the only study that studied angiopoietin-2 in serum.
Also in a previous semiquantitative reverse transcriptase–poly-
merase chain reaction and immunohistochemistry study, the
tissue levels of angiopoietin-2 and VEGF expression were cor-
related and showed high signiﬁcance in NSCLC [24].
Other marker that was studied is survivin, one of the inhib-
itors of apoptosis, which promotes cell proliferation and in-
duces angiogenesis [8]. It shows a signiﬁcant difference in the
expression between malignant and normal adult cells, with
very low to absent levels in the normal adult tissue but in-
creased levels in a wide variety of solid tumors [22]. In tumors,
the positive expression of survivin correlates with more aggres-
sive behavior and poorer prognosis [25].
This study based on the measurements of survivin concen-
trations in serum did not conﬁrm these observations. We
proved that survivin concentrations were the same in patients
Table 2 Relation of serum angiopoietin-2 and survivin levels with cell types.a
Squamous (25) Adenocarcinoma (35) Large cell (10) p-Value
Angiopoietin-2 (pg/mL) 2730 (1617–5481) 3059 (1171–6541) 2100 (1621–3268) 0.193
Survivin (pg/mL) 55.6 (46.1–96.3) 53.0 (39.3–85.5) 50.2 (44.8–57.0) 0.431
a Data were represented as median and range.
Table 3 Relation of serum angiopoietin-2 and survivin with clinico-pathological characteristics in NSCLC.a
Variables Case no. Angiopoietin-2 (pg/mL) p-Value Survivin (pg/mL) p-Value
Grade
1, 2 36 2873 (1171–5002) 0.563 53.0 (42.0–85.5) 0.581
3, 4 34 2916 (1439–6541) 55.6 (39.3–96.3)
Distant metastasis
No 55 3016 (1171–6541) 0.781 53.0 (42.0–96.3) 0.246
Yes 15 2929 (1439–5090) 50.2 (39.3–62.4)
Stage
2, 3 51 3238 (1171–6541) 0.106 53.0 (39.3–96.3) 0.223
4 19 2409 (1439–3835) 57.0 (44.8–84.1)
Smoking
No 20 2932 (1171–5481) 0.528 56.3 (39.3–85.5) 0.747
Yes 50 2873 (1502–6541) 53.0 (42.0–96.3)
a Data were represented as median and range.














Figure 2 ROC curve for the serum angiopoietin-2 differentiating
lung cancer and control groups (area under the curve 0.832).














Figure 3 ROC curve for the serum survivin differentiating the
lung cancer and control groups (area under the curve 0.672).
44 A. Fawzy et al.with NSCLC as in healthy people .These results were in agree-
ment with Naumnik’s et al. ﬁndings [25], Fan’s et al. [26] and
studies among patients with other cancers [27] who measured
survivin in the serum. Also with Yagihashi’s et al. [28] using
monoclonal antibodies in patients with advanced non-small
cell lung carcinoma.
Other literatures showed that survivin overexpression was
found in lung cancer, but it was not observed in other lung
tissue lesions [13,29,30]. This discrepancy between our results
and data in literature may be due to that most previous studies
on apoptosis have evaluated survivin expression by different
techniques as reverse transcriptase polymerase chain reaction(RT-PCR) and/or in parafﬁn-embedded materials by immuno-
histochemistry (IHC) or by In Situ Hybridization(ISH) not by
ELIZA. Also this ﬁnding may be explained by the different
material used in which we assessed survivin levels in serum
whereas all the other studies assessed survivin in tumor tissues.
Signiﬁcance of survivin expression in the prognosis of
NSCLC patients is not well characterized. Yie and his col-
leagues [12] found that patients with mRNA survivin positive
circulating cells were detected in patients with NSCLC even at
early stage. In agreement with this study, two other studies re-
ported that survivin expression in tumor tissue is a predictor of
Importance of serum levels of angiopoietin-2 and survivin biomarkers in non-small cell lung cancer 45shortened survival in NSCLC [14,32]. In contrast to these stud-
ies, Vischioni and his colleagues [33] and Falleni with his col-
leagues [13] reported that survivin expression in tumor
tissues did not correlate with worse prognosis in NSCLC.
In this study serum angiopoietin-2was measured by ELIZA
technique, so by simple method with less cost, higher through-
put, more ﬂexibility and small volume. We can measure this
marker than other sophisticated method and can be used as
a potential marker for early detection of NSCLC.Conclusion
Angiopoietin-2 is a useful marker for diagnosis of NSCLC by
ELIZA technique but serum survivin has no clinical signiﬁ-
cance in NSCLC and further studies should clarify their clini-
cal validity and prognostic implications.References
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